Focused on specialist medicines
Orphidis focuses on innovative therapies where treatment is specialist-led and patient identification, access and execution at the right treatment centres are critical.
Therapeutic areas
Our therapeutic focus
Rare
Disease
Small, often underdiagnosed populations where patient identification and access are central.
- Patient pathway and referral mapping
- Specialist physician and treatment-centre engagement
- Managed access and named-patient programmes
Oncology / Hematology
Innovative cancer therapies delivered through specialist centres and hospital access pathways
- Treatment-centre and specialist prioritisation
- Hospital listing and funding pathways
- Medical engagement around diagnosis and treatment
Specialty
Medicines
Hospital-administered and high-value therapies where specialist prescribing and access determine uptake
- Physician requests and patient eligibility documentation
- Coordinated supply to treating hospitals
- Focused access, medical and operational support rather than broad primary-care infrastructure
Why specialist medicines require a different model
Concentrated patient populations
Patients may be treated in a limited number of specialist centres, making precision more important than commercial scale
Patient identification
Finding the right patients and understanding diagnosis and referral pathways can matter as much as product awareness
Complex access
Registration alone does not guarantee access. Reimbursement, private funding, hospital processes and named-patient pathways all influence how a medicine reaches patients
Focused execution
Resources go where they matter most: the centres, physicians and access pathways that determine treatment
Rare disease at scale
Rare diseases are individually uncommon but collectively affect a significant number of people.
~90–150M
People estimated to be living with a rare disease across our current market focus.
Estimate based on a global rare-disease prevalence of 3.5–5.9% applied to approximately 2.5 billion people. Sources: Nguengang Wakap et al., European Journal of Human Genetics (2020); UN World Population Prospects 2024.
Let’s talk
Exploring a specialist medicine in Asia?
Whether you are considering managed access, registration or broader commercialisation, we’d welcome a conversation.
